Allosteric regulation of epidermal growth factor (EGF) receptor ligand binding by tyrosine kinase inhibitors

Keyphrases

• Epidermal Growth Factor Receptor 100%
• Tyrosine Kinase Inhibitor 100%
• Receptor-ligand Binding 100%
• Allosteric Regulation 100%
• Epidermal Growth Factor Receptor Ligands 100%
• Kinase Domain 50%
• Extracellular Domain 33%
• Extracellular Signal-regulated Kinase 33%
• Small Molecule Tyrosine Kinase Inhibitors 33%
• Tumor 16%
• Cell Growth 16%
• Tumor Subtype 16%
• Receptor Tyrosine Kinase 16%
• Monoclonal Antibody 16%
• Tyrosine Kinase Activity 16%
• Ligand-binding Domain 16%
• Ligand Binding 16%
• Positive Cooperativity 16%
• Kinase Activity 16%
• Allosteric Regulators 16%
• Receptor Binding Affinity 16%
• Differential Effectiveness 16%
• Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI) 16%
• Functional Coupling 16%
• Receptor Subunits 16%
• Intracellular Domain 16%
• Kinase mutation 16%
• Conformational Equilibrium 16%
• Inhibitor Antibodies 16%
• ATP-competitive 16%
• Type II Inhibitor 16%

Biochemistry, Genetics and Molecular Biology

• Epidermal Growth Factor Receptor 100%
• Ligand Binding 100%
• Tyrosine Kinase Inhibitor 100%
• Allosteric Regulation 100%
• Kinase 50%
• Phosphotransferase 50%
• Conformation 37%
• Receptor Tyrosine Kinase 25%
• Small Molecule 25%
• Cell Growth 12%
• Tyrosine Kinase 12%
• Adenosine Triphosphate 12%
• Cooperation 12%
• Binding Affinity 12%
• Ligand Binding Domain 12%
• Monoclonal Antibody 12%
• Receptor Tyrosine Kinase Inhibitors 12%
• Receptor Binding 12%